688235:SHA
BeOne Medicines AG
CNÂ¥262.00
arrow_upward
+1.01%(+2.63) 1D
Oct 20, 3:00:01 PM GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CNÂ¥257.50
High
CNÂ¥262.38
Low
CNÂ¥256.05
Mkt. cap
303.44B
Avg. vol.
2.90M
Volume
2.65M
P/E ratio
93.58
52-wk high
CNÂ¥319.24
52-wk low
CNÂ¥205.51
EPS
CNÂ¥2.80
No. of employees
12K
Open
CNÂ¥257.50
High
CNÂ¥262.38
Low
CNÂ¥256.05
Mkt. cap
303.44B
Avg. vol.
2.90M
Volume
2.65M
P/E ratio
93.58
52-wk high
CNÂ¥319.24
52-wk low
CNÂ¥205.51
EPS
CNÂ¥2.80
No. of employees
12K
News stories
From web sources and news partners
ad-hoc-news.de
·
3 hours ago
Morgan Stanley raises target for BeOne Medicines stock to USD 425.00
Simply Wall Street
·
16 hours ago
Did ESMO 2026 Cancer Data Just Shift BeOne Medicines' (ONC) Investment Narrative?
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com